RNXT: RenovoCath's commercial and clinical momentum accelerates with strong survival data and expanding adoption

RenovoCath's targeted drug delivery system is gaining rapid commercial traction, now in 21 centers with plans to exceed 35 by year-end. Interim phase III data show a six-month survival benefit and 65% reduction in toxicities, supporting raised revenue guidance and expansion into new cancer indicati…